Literature DB >> 21491106

Tackling frontal lobe-related functions in PKU through functional brain imaging: a Stroop task in adult patients.

Benedikt Sundermann1, Bettina Pfleiderer, Harald E Möller, Wolfram Schwindt, Josef Weglage, Jöran Lepsien, Reinhold Feldmann.   

Abstract

BACKGROUND: Profound mental retardation in phenylketonuria (PKU) can be prevented by a low phenylalanine (Phe) diet. However, even patients treated early have inconsistently shown deficits in several frontal lobe-related neuropsychological tasks such as the widely accepted Stroop task. The goal of this study was to investigate whether adult patients exhibit altered brain activation in Stroop-related locations in comparison to healthy controls and if an acute increase in blood Phe levels in patients has an effect on activation patterns.
METHODS: Seventeen male, early-treated patients with classic PKU (mean ± SD age: 31.0 ± 5.2 years) and 15 male healthy controls (32.1 ± 6.4 years) were compared using a color-word matching Stroop task in a functional magnetic resonance imaging (fMRI) study at 3T. Participants were scanned twice, and an oral Phe load (100 mg/kg body weight) was administered to patients prior to one of the fMRI sessions (placebo-controlled). Activity in brain regions that are known to be involved in Stroop tasks was assessed.
RESULTS: PKU patients exhibited poorer accuracy in incongruent trials. Reaction times were not significantly different. There were no consistent differences in BOLD activations in Stroop-associated brain regions. The oral Phe administration had no significant effect on brain activity.
CONCLUSIONS: Neither a generally slower task performance nor distinctively altered functioning of brain networks involved in a task representing a subset of dopamine-dependent executive functions could be proven. Decreased accuracy and inconsistent findings in posterior areas necessitate further study of frontal-lobe functioning in PKU patients in larger study samples.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21491106     DOI: 10.1007/s10545-011-9318-4

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  65 in total

1.  Dopaminergic regulation of cerebral cortical microcirculation.

Authors:  L S Krimer; E C Muly; G V Williams; P S Goldman-Rakic
Journal:  Nat Neurosci       Date:  1998-08       Impact factor: 24.884

2.  Neurogenic control of the cerebral microcirculation: is dopamine minding the store?

Authors:  C Iadecola
Journal:  Nat Neurosci       Date:  1998-08       Impact factor: 24.884

3.  The visual what for area: words and pictures in the left fusiform gyrus.

Authors:  Randi Starrfelt; Christian Gerlach
Journal:  Neuroimage       Date:  2007-01-18       Impact factor: 6.556

4.  Self-assessed and objective blood phenylalanine levels in patients with early treated phenylketonuria.

Authors:  Josef Weglage; Harald E Möller; Reinhold Feldmann
Journal:  Acta Paediatr       Date:  2010-02-02       Impact factor: 2.299

5.  Neuropsychology of early-treated phenylketonuria: specific executive function deficits.

Authors:  M C Welsh; B F Pennington; S Ozonoff; B Rouse; E R McCabe
Journal:  Child Dev       Date:  1990-12

6.  Executive functioning, memory, and learning in phenylketonuria.

Authors:  Shelley Channon; Elaine German; Cristina Cassina; Philip Lee
Journal:  Neuropsychology       Date:  2004-10       Impact factor: 3.295

7.  Cerebral energy metabolism in phenylketonuria: findings by quantitative In vivo 31P MR spectroscopy.

Authors:  Joachim Pietz; André Rupp; Friedrich Ebinger; Dietz Rating; Ertan Mayatepek; Chris Boesch; Roland Kreis
Journal:  Pediatr Res       Date:  2003-02-20       Impact factor: 3.756

8.  Mesocortical dopamine neurons: high basal firing frequency predicts tyrosine dependence of dopamine synthesis.

Authors:  S Y Tam; J D Elsworth; C W Bradberry; R H Roth
Journal:  J Neural Transm Gen Sect       Date:  1990

9.  Meta-analysis of neuropsychological symptoms of adolescents and adults with PKU.

Authors:  J J Moyle; A M Fox; M Arthur; M Bynevelt; J R Burnett
Journal:  Neuropsychol Rev       Date:  2007-04-05       Impact factor: 7.444

10.  The pathogenesis of the white matter abnormalities in phenylketonuria. A multimodal 3.0 tesla MRI and magnetic resonance spectroscopy (1H MRS) study.

Authors:  V Leuzzi; M Tosetti; D Montanaro; C Carducci; C Artiola; C Carducci; I Antonozzi; M Burroni; F Carnevale; F Chiarotti; T Popolizio; G M Giannatempo; V D'Alesio; T Scarabino
Journal:  J Inherit Metab Dis       Date:  2007-01-23       Impact factor: 4.750

View more
  5 in total

Review 1.  New frontiers in neuroimaging applications to inborn errors of metabolism.

Authors:  Morgan J Prust; Andrea L Gropman; Natalie Hauser
Journal:  Mol Genet Metab       Date:  2011-06-30       Impact factor: 4.797

Review 2.  Systematic Review and Meta-Analysis of Neuropsychiatric Symptoms and Executive Functioning in Adults With Phenylketonuria.

Authors:  Deborah A Bilder; J Kay Noel; Erin R Baker; William Irish; Yinpu Chen; Markus J Merilainen; Suyash Prasad; Barbara J Winslow
Journal:  Dev Neuropsychol       Date:  2016-11-02       Impact factor: 2.253

3.  Cognitive outcomes in early-treated adults with phenylketonuria (PKU): A comprehensive picture across domains.

Authors:  Liana Palermo; Tarekegn Geberhiwot; Anita MacDonald; Ellie Limback; S Kate Hall; Cristina Romani
Journal:  Neuropsychology       Date:  2017-01-12       Impact factor: 3.295

4.  The impact of phenylalanine levels on cognitive outcomes in adults with phenylketonuria: Effects across tasks and developmental stages.

Authors:  Cristina Romani; Liana Palermo; Anita MacDonald; Ellie Limback; S Kate Hall; Tarekegn Geberhiwot
Journal:  Neuropsychology       Date:  2017-03       Impact factor: 3.295

5.  Impact of phenylalanine on cognitive, cerebral, and neurometabolic parameters in adult patients with phenylketonuria (the PICO study): a randomized, placebo-controlled, crossover, noninferiority trial.

Authors:  Roman Trepp; Raphaela Muri; Stephanie Abgottspon; Lenka Bosanska; Michel Hochuli; Johannes Slotboom; Christian Rummel; Roland Kreis; Regula Everts
Journal:  Trials       Date:  2020-02-13       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.